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iarrhea and constipation are known risk factors for
ecal incontinence. This report reviews how to diagnose
nd medically treat patients with chronic diarrhea,
hronic constipation with overflow incontinence, and in-
ontinence resulting from rectal mucosal prolapse sec-
ndary to hemorrhoids. Antidiarrheal agents (including
operamide, diphenoxylate, and difenoxin) and the tricy-
lic antidepressant amitriptyline improve continence in
atients with diarrhea-associated incontinence. Other
ntidiarrheal agents are under investigation. The mech-
nism is believed to be decreased intestinal motility and
tool frequency resulting in more formed stools. In-
reases in anal canal resting pressure may also contrib-
te to improvement in continence. Adverse effects are
onstipation from excessive use. In addition to antidiar-
heal drugs, fiber supplements may improve inconti-
ence associated with diarrhea. Transient, benign cases
f constipation usually respond to increasing fluid intake
nd dietary fiber, improving mobility, or eliminating the
oncurrent use of constipating drugs. For mild to mod-
rate constipation, bulking agents, laxatives, and stool
ofteners are used cautiously so as not to excessively
oosen stools and exacerbate anal incontinence. Laxa-
ives have been shown to improve continence, possibly
hrough the mechanism of eliminating fecal impaction.
rolapsing hemorrhoids may partially obstruct defeca-
ion and cause soilage from the passage of fecal mate-
ial, mucus, or blood. With endoscopic banding, a ligator
s attached to an endoscope and a tight band is placed
round the enlarged vein, causing the hemorrhoid to
hrombose.
ecal incontinence is a condition with well-docu-
mented adverse physical, social, psychological, and
conomic consequences. Estimates of its prevalence,
hich range from 2%1 to 7%2 in the community-dwell-
ng population to 45% or more3,4 among institutional-
zed persons, are probably low because of individual
eluctance to discuss the embarrassing condition. Pa-
ients report that fecal incontinence can have a devastat-
ng effect on employment, social interaction, self-esteem,
nd overall quality of life.5,6
Diarrhea and constipation are recognized as indepen-
ent risk factors of fecal incontinence,3,7,8 and the med-
cal management of fecal incontinence is directed pri-arily toward the treatment of diarrhea and
onstipation. By contrast, surgical and behavioral treat-
ents focus more on the strength of the pelvic floor
uscles and the ability to perceive rectal filling in pa-
ients with fecal incontinence secondary to neurologic
nd anatomic defects. Medical management is frequently
ombined with surgical or behavioral treatment because
onstipation or diarrhea may exacerbate incontinence
ssociated with neurologic and anatomic defects.
Pathophysiology and Diagnosis
Numerous medical conditions can affect the anat-
my and function of the anorectal muscles and the pelvic
oor and thereby place individuals at risk for fecal in-
ontinence. Injuries associated with childbirth, anorectal
urgery, anorectal trauma, inflammatory processes, and
umors are typical causes of anatomic sphincter muscle
isruption. Pelvic floor muscle and anal sphincter dener-
ation can result from injury during childbirth, neurop-
thy, spinal cord injury, and congenital abnormalities
uch as spina bifida and myelomeningocele. Neurologic
onditions such as dementia, cerebrovascular accident,
ultiple sclerosis, tertiary syphilis, brain tumor, and
auda equina syndrome can also contribute to fecal in-
ontinence.
Diarrhea and constipation are 2 common conditions
hat exacerbate fecal incontinence. Most cases of diarrhea
esult from disorders related to water and electrolyte
ransport in the intestinal tract. Excess secretion of elec-
rolytes and water into the intestinal lumen, the loss of
rotein and fluid from the mucosa, and increased osmotic
oad in the intestine can alter intestinal motility and
ecrease stool transit time. The more common underly-
ng pathologies associated with chronic diarrhea include
rritable bowel syndrome (IBS), Crohn’s disease, ulcer-
tive colitis, small-bowel bacterial overgrowth, short-
owel syndrome, bile acid malabsorption, celiac disease,
icroscopic colitis, and diabetic diarrhea. Although con-
Abbreviations used in this paper: CNS, central nervous system; IBS,
rritable bowel syndrome.



























































































S56 YOLANDA SCARLETT GASTROENTEROLOGY Vol. 126, No. 1tipation is generally regarded as benign, chronic cases
eft untreated may lead to fecal impaction with overflow
ncontinence. Typical causes of constipation include lack
f dietary fiber, immobility, neurogenic disorders, sys-
emic illnesses, and medications.
This report focuses on how to properly diagnose and
edically treat patients with chronic diarrhea (including
hat related to IBS), chronic constipation with overflow
ncontinence, and incontinence resulting from rectal mu-
osal prolapse secondary to hemorrhoids.
Evaluating Patients and
Choosing a Treatment Option
Compiling a detailed medical history and per-
orming a comprehensive examination can provide essen-
ial information to help guide the treatment of patients
ith fecal incontinence. Important facts to deduce from
he patient history and examination are the total number
f bowel movements and the number of incontinent
pisodes in a 7-day period, stool consistency and the
olume of stool loss, awareness of stool passage, and
hether the rectal vault is being completely evacuated.
ecal incontinence is rarely caused by a single factor, so
iagnostic evaluation of the afferent and efferent inner-
ation and structural muscle integrity of the external
nal sphincter and pelvic floor may be necessary to pin-
oint the underlying pathology.9 Anorectal manometry,
lectromyography, pudendal nerve latency testing, and
ltrasound imaging of the anal sphincter are used to
valuate motor function, nerve function, and anatomic
tructure of the pelvis. If the patient has constipation
ith overflow incontinence, the use of radiopaque colonic
ransit markers can help determine colonic transit time
nd identify marker retention patterns consistent with
utlet obstruction. Defecography with soft barium paste
an also render useful information about the anorectal
ngle, pelvic floor descent, and rectal prolapse that may
ontribute to fecal incontinence.
Ultimately, the aim of medical management is to
dentify and treat the underlying disorders causing diar-
hea or constipation, relieve symptoms, restore bowel
ontrol, and improve quality of life. However, when
hese disorders cannot be identified or reversed, medical




Pharmacotherapy is usually reserved for patients
ith more persistent diarrhea that does not respond to
onservative treatments such as bulking agents. Nonspe-ific antidiarrheal agents decrease intestinal motility and
ecrease stool frequency, which may in turn limit the
umber of incontinent episodes. Modifying stool consis-
ency is also a primary goal, because formed stool is easier
o control than loose stool. Practitioners should always be
indful of the possible constipating effects of excessive
se of antidiarrheal agents.
Loperamide
A synthetic opioid with an excellent safety profile,
operamide has been found to be effective in treating
raveler’s diarrhea and acute diarrhea and has been used
s an adjunctive treatment of nearly all forms of chronic
iarrhea. Loperamide acts directly on the intestine to
nhibit peristalsis, lengthens small intestinal and mouth-
o-cecum transit time, increases sphincter tone and rest-
ng pressure, and reduces urgency, stool volume, and
requency of bowel movements.10 Its mechanism of ac-
ion is to increase mucosal contact time, allowing for
ore complete absorption of electrolytes and water. The
ntidiarrheal activity of loperamide may derive from its
unctioning as both a calcium receptor antagonist and a
alcium channel blocker.11 Loperamide may also reduce
he sensitivity of the rectoanal inhibitory reflex and
ncrease rectal perception in healthy subjects.12 Loper-
mide does not cross the blood-brain barrier and has no
ddiction potential.
In a double-blind, crossover study of 30 subjects with
hronic diarrhea,13 loperamide, codeine, and diphenoxy-
ate decreased stool frequency to the same degree but
operamide and codeine were more effective than diphe-
oxylate in decreasing the sense of urgency that was often
ssociated with fecal incontinence in these patients. Pre-
ious research14 suggested that loperamide improves
ontrol of urgency by increasing anal tone and improving
olonic tolerance of fluid load introduced into the rec-
um. Palmer et al. reported that patients treated with
iphenoxylate experienced more adverse effects, includ-
ng central nervous system (CNS) symptoms. The inves-
igators concluded that the primary drawback of loper-
mide was that it tended to be too potent and produced
onstipation and abdominal pain.13 Titrating the dosage
lowly upward helped relieve these adverse symptoms
Table 1). Loperamide is available as a liquid formulation
hat is useful for titrating low doses.
Loperamide has been found to be superior to diphe-
oxylate in reducing stool frequency and improving con-
istency of stools in patients with chronic diarrhea after
ntestinal resection15 and was more effective than bis-
uth subsalicylate in reducing the number of unformed
tools for patients with acute traveler’s diarrhea.16 Nu-
















































January Supplement 2004 MEDICAL MANAGEMENT OF FECAL INCONTINENCE S57afely and effectively reduce noninfectious diarrhea in
hildren. Fifty-three young children with acute diarrhea
n a hospital setting who received 0.8 mg  kg1  day1
f loperamide recovered from their symptoms faster and
egained weight faster than children who received 0.4
g  kg1  day1 or placebo.17
Specific benefits for loperamide in the treatment of
ecal incontinence were observed in an early study by
ead et al. that compared loperamide 4 mg daily with
lacebo.18 These investigators found that loperamide re-
uced urgency and incontinence, increased anal canal
esting pressure, and improved the ability to retain saline
nfused into the rectum. In another crossover study,
allgren et al. showed that loperamide improved passive
ncontinence following proctocolectomy.19 Arnbjornsson
t al. reported in an uncontrolled trial that loperamide
mproved continence in children following rectoplasty
or high imperforate anus.20
Diphenoxylate and Difenoxin
These opioid derivatives inhibit intestinal motil-
ty and propulsion. Because they cross the blood–brain
arrier and can cause mild euphoria, atropine is added in
ubtherapeutic amounts to reduce the potential for over-
able 1. Dosing Guidelines for Common Fecal Incontinence M
Medication Precautions
operamide Use cautiously in patients with
active inflammatory disease of
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losetron Reintroduced/approved by the
Food and Drug Administration
as unlabeled investigational









henylephrine gel Experiments restricted to patients
who were not pregnant and did
not have ischemic heart
disease, aortic aneurysm,







lesseose and abuse. As antidiarrheal agents, diphenoxylate
nd difenoxin exhibit a slightly more potent effect than
orphine but are not nearly as potent as loperamide.
oth agents are appropriate for adult and pediatric pop-
lations.
Despite their generally favorable safety profiles, diphe-
oxylate and difenoxin in high doses can produce adverse
NS effects and the adjunctive atropine may cause anti-
holinergic effects. Excessive use or overdose may cause
onstipation and, if inflammatory conditions preexist,
ay promote the development of toxic megacolon.
Few large, double-blind, controlled trials have com-
ared diphenoxylate and difenoxin with other antidiar-
heal agents or placebo. Fifteen patients with chronic
iarrhea and fecal incontinence treated either with di-
henoxylate plus atropine or placebo experienced no
ffect on rectal or anal sphincter pressures, but the di-
henoxylate-treated patients had reduced stool frequency
nd stool volume.21 The investigators recommended the
gent for temporary or intermittent therapy. Diphenoxy-
ate did not prove superior to kaolin-pectin suspension
ormulas in reducing the frequency of bowel movements,





ach subsequent loose stool
g/day. Maximum daily
r children: 3 mg, age 2–5 yr;
6–8 yr; 6 mg, age 8–12 yr.
ard slowly.
Overdosage may result in CNS
depression and paralytic ileus;
children may be more sensitive
to CNS effects. Other reported
effects include rash, dizziness,
fatigue, cramping, constipation,
dry mouth, nausea, and
vomiting.
contain 25 g atropine
r tablet with either 2.5 mg
ate or 1 mg difenoxin




(if previous inflammation), and
CNS effects. Atropine may
cause anticholinergic effects
(dry mouth, blurred vision).
Other effects are drowsiness
and urinary retention.
imited to physicians enrolled
ithKline program. Dosing:
; may be increased to 1 mg
if no response after 4
e if no improvement at 1 mg
after 4 weeks.
Constipation with excessive
dosage. Ischemic colitis severe
enough to be fatal.
ts, 2.5-cm application at
concentration had a
c effect for most patients at
act concentration seems
rtant to achieve initial effect;
centrations can maintain.




















































































































S58 YOLANDA SCARLETT GASTROENTEROLOGY Vol. 126, No. 1Bulk-Forming and Hydroscopic Agents
Although these agents are used for constipation,
hey can also alleviate mild chronic diarrhea by absorbing
ater and increasing stool bulk and possibly by creating
he perception of decreased stool fluidity. Kaopectate, an
ver-the-counter preparation containing activated atta-
ulgite, can relieve mild symptoms of diarrhea by de-
reasing the fluidity of the stool. Bliss et al. showed in a
ontrolled study that fiber supplements (psyllium and
um agar) were more effective than placebo in reducing
ncontinence for patients who had fecal incontinence or
oose or watery stools; the improvements were associated
ith more formed stools.22
Bismuth Salicylate
This combination of bismuth and subsalicylate
uspended in a mixture of magnesium aluminum silicate
lay seems to inhibit secretions, inflammation, and mi-
robial development. Bismuth salicylate has been effec-
ive in preventing and treating traveler’s diarrhea, and it
ay alleviate symptoms of nonsyndromic, episodic diar-
hea. It is safe if taken at recommended dosages. The
gent is not nearly as potent as loperamide and in head-
o-head, open-label comparisons was not as effective as
operamide in treating acute nondysenteric traveler’s di-
rrhea16 and acute diarrhea.23
Phenylephrine Gel
Phenylephrine gel is not currently approved for
he treatment of fecal incontinence but is being tested in
linical trials. Phenylephrine is a selective 1-adrenergic
gonist used as a nasal decongestant and as a vasocon-
trictor in hypotension. The agent resembles naturally
ccurring catecholamines and can interact with 1- or
1-adrenergic receptors to produce sympathomimetic ef-
ects.24 Phenylephrine gel modulates the extrinsic inner-
ation (vascular smooth muscle tissue) of the internal
nal sphincter muscles to increase anal sphincter tone and
elp maintain anal canal resting pressure. The agent thus
olds promise for subjects with passive fecal incontinence
ho have intact internal anal sphincter muscles associ-
ted with low resting anal sphincter pressure.
In 1999, British researchers initially applied the agent
o 12 healthy volunteers and found a dose-dependent
ncrease in maximum resting anal pressure, including a
3% increase with the use of 10% topical gel.25 There
as no further improvement at concentrations 30%.
owever, in a subsequent trial26 involving 10 patients
ith weak but intact internal anal sphincter muscles and
assive fecal incontinence, they applied phenylephrine
el concentrations of 10%, 20%, 30%, and 40% or
lacebo gel to the anus. There was a clear dose-responseelationship at 1 hour after application, and at both 1 and
hours, maximum anal resting pressure (MRP) was
ncreased with all concentrations of the pheylephrine gel;
he increase was statistically significant (P  0.05 com-
ared with placebo) with the 30% and 40% concentra-
ions, and median MRP values reached the normal range
Figure 1). Side effects were minimal, and for all patients,
ocal discomfort settled within 20 minutes. The out-
omes suggest that the exact initial concentration may be
mportant for saturating relevant receptors throughout
he anoderm. The investigators concluded that phenyl-
phrine gel has the potential to achieve a sustained
linical response in subjects who have passive or urge
ncontinence but intact, functioning sphincters. The
gent may possibly improve function for persons with
tructural damage to the sphincter.26
Amitriptyline
This older tricyclic antidepressant (which pos-
esses anticholinergic, serotonergic, and antimuscarinic
roperties that affect the functions of the colon, rectum,
nd anal sphincter) has been used empirically to improve
ymptoms for patients with idiopathic fecal incontinence
r IBS.27,28 The promise of low-dose amitriptyline is its
bility to reduce the amplitude and frequency of rectal
otor complexes, periods of powerful phasic contrac-
ions, possibly through an anticholinergic mechanism.
In an open-label study, 18 patients (2 men) with
diopathic fecal incontinence who received low-dose (20
g daily) amitriptyline for 4 weeks and 24 healthy
ontrol subjects who did not receive the agent were
valuated.29 Treatment prolonged colonic transit time
nd led to the formation of firmer stools that were passed
ore frequently. Sixteen of the 18 amitriptyline-treated
atients (89%) had statistically significant improvements
n incontinence scores, from a median of 16 (on a scale
rom 1 to 18) before treatment to a median of 3 after
reatment (P  0.001). Thirteen patients (72%) had full
emission of symptoms with complete stool control at
-month follow-up. Treatment significantly reduced the
mplitude (median rectal pressure, 94 vs. 58 cm H2O)
nd frequency (4.5 vs. 1.2 per hour; P  0.01) of rectal
otor complexes as assessed by 24-hour ambulatory
norectal manometry. Santoro et al. also found that am-
triptyline possibly diminished the increased anorectal
ressures exerted during rectal motor complexes that
ay overcome sphincter resistance and cause inconti-
ence.29 A randomized, placebo-controlled, variable-
ose, multicenter trial is needed to determine whether
mitriptyline can alter rectal function as an independent















































Adapted and reprinted with permission from Cheetham et al.
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The 5-HT3 receptor antagonists such as alosetron
nd cilansetron appear to inhibit the excitatory effects of
-HT3 receptors on both ascending and descending neu-
onal pathways involved in peristalsis. By slowing co-
onic transit, increasing “compliance” of the colon to
istention, and decreasing visceral hypersensitivity,
-HT3 antagonists may be appropriate for treating pa-
ients with diarrhea-predominant IBS. Table 2 lists the
echanisms by which these agents are believed to influ-
nce gastrointestinal tract function.30
Alosetron
After being approved by the U.S. Food and Drug
dministration in February 2000, alosetron was found to
ause occasional severe side effects of ischemia and con-
tipation. Physicians must now sign an agreement pledg-
ng that they understand how to diagnose and treat IBS
nd how to prescribe alosetron. Patients must also sign
n agreement that they acknowledge the risks of taking
losetron. Prescriptions now have cautionary labeling,
nd recommended dosages have been halved.31 Although
losetron is an effective antidiarrheal agent, there are no
eported data showing that it improves continence.
Medical Management
of Constipation
Constipation has traditionally been difficult to
efine because of great variation in symptomatology.
onstipation with pelvic floor outlet obstruction or pel-
ic floor dyssynergia can contribute to fecal impaction
ith resultant overflow incontinence, as can medications
uch as narcotic analgesics and antimotility drugs. Gen-
rally, constipation is defined as 3 bowel movements
er week, difficulty initiating or passing stools, passage
f exceedingly firm or small-volume stools, straining, or
feeling of incomplete evacuation.
Cases of transient, benign constipation are highly
reatable and can usually be traced to reversible factors
uch as immobility, lack of dietary fiber, poor fluid
ntake/dehydration, and the concurrent use of constipat-
ng drugs. Cases of chronic constipation may be more
hallenging to treat, because there may be underlying
ystemic disease or neurologic dysfunction contributing
o the constipation. Treating physicians should seek to
solate the underlying pathophysiology either as delayed
olonic transit (colonic inertia, slow-transit idiopathic
onstipation) or as a defecation (evacuation) disorder,
hich may be related to neurologic dysfunction or inap-
ropriate relaxation of the pelvic floor when attempting
o evacuate.32 Pelvic floor disorders affect women dispro-igure 1. Effect of a single application of placebo gel or phenylephrine gel
n maximum anal resting pressure (MRP) in 10 patients with fecal inconti-
ence, measured before and 1 hour after application (broken line represents
edian values). (A) Patients were given placebo gel. (B) Patients were given































































S60 YOLANDA SCARLETT GASTROENTEROLOGY Vol. 126, No. 1ortionately and are usually accompanied by excessive
training during defecation and a sense of incomplete
ectal emptying. Retained stool can decrease the internal
nal sphincter pressure and allow liquid stool to seep
rom the anal canal, causing fecal incontinence.
Laxatives are used in the management of constipation
nd act in one of 3 ways: by retaining intraluminal fluid
hrough hydrophilic or osmotic mechanisms, decreasing
et fluid absorption and thereby altering small and large
owel fluid and electrolyte transport, or affecting motil-
ty either through the inhibition of segmental (nonpro-
ulsive) contractions or the stimulation of propulsive
ontractions.33 Bulking agents, laxatives, and stool soft-
ners must be used cautiously so as not to loosen stools
xcessively and exacerbate anal incontinence, particularly
f anal sphincter pressures are lowered.
Laxative regimens have been shown to improve fecal
ncontinence both for children34,35 and institutionalized
dults.36 Stimulant laxatives and polyethelene glycol
eem to work better than enemas.
Dietary Fiber
Many cases of mild or transient constipation can
e relieved by increasing dietary fiber intake to increase
tool weight and soften the consistency of stools. Wheat
ran has high lignin content, which increases stool
eight. Psyllium husk, derived from the plantago seed,
s a common ingredient in commercial fiber agents.
ynthetic celluloses such as methylcellulose and polycar-
ophils are poorly fermentable compounds that help
bsorb water and increase stool bulk. Abdominal pain
nd bloating, the 2 most common adverse symptoms of
reater fiber intake, usually decrease over time and may
able 2. Mechanisms by Which 5-HT3 Receptor Antagonists
Function/location
of receptors Proposed mechanism
otility
Excitatory enteric neurons Reduced transmitter release
(e.g., acetylcholine, tachykinin)










Enteric and CNS neurons;
enterochromaffin cells
Blockade of effects of chemotherap
release of serotonin
dapted and reprinted with permission from Mayer et al.30e avoided by increasing intake gradually. Consumption
f fiber is contraindicated if the patient has obstructive
ymptoms or fecal impaction.33,37 In one study, patients
ith chronic constipation who had slow gastrointestinal
ransit or other defecation disorders were less likely to
espond to dietary fiber therapy than patients who did
ot exhibit an underlying pathology.37
Nonabsorbable Sugars and Alcohols
Lactulose and sorbitol, nonabsorbable sugars that
re hydrolyzed into organic acids, draw water osmotically
nto the intestinal lumen to stimulate colonic propulsion
nd motility. Lactulose and sorbitol have been shown to
e equally effective in relieving idiopathic constipation
n elderly subjects; lactulose is less expensive. The agents
ay not take effect for 24–48 hours, during which time
atients may experience abdominal discomfort or disten-
ion or flatulence that usually abates with continued
reatment.33 When administered rectally, glycerin, a tri-
ydroxy alcohol, promotes water retention to stimulate
eristalsis and usually produces a bowel movement
ithin an hour. It may cause mild rectal discomfort, a
urning sensation, and minimal bleeding.
Saline Laxatives
The phosphate anions or magnesium cations in
aline laxatives (sodium phosphate, magnesium sulfate,
agnesium citrate, and magnesium hydroxide) are be-
ieved to mediate water retention osmotically to stimu-
ate peristalsis. Magnesium may also stimulate the re-
ease of inflammatory mediators that boost the
roduction of intraluminal fluids and electrolytes that
ncrease intestinal motility. Because sodium phosphate is
Influence Gastrointestinal Tract Function
Expected effect
Reduced ascending contraction (inhibition of peristalsis)
Enhanced compliance
Reduced descending relaxation (inhibition of peristalsis)
Intrinsic neurons: peristalsis triggered at higher thresholds
Extrinsic neurons: reduced visceral nociception and
inhibition of reflex behaviors induced by intestinal
distention (e.g., variations in blood pressure)




























































































January Supplement 2004 MEDICAL MANAGEMENT OF FECAL INCONTINENCE S61etter absorbed than magnesium compounds, it needs to
e administered in larger doses for therapeutic effect.
aline laxatives are well tolerated but should be used
autiously in patients with cardiac disease, renal insuffi-
iency, or electrolyte abnormalities.
Tegaserod and Cisapride
Tegaserod, a partial 5-HT4 agonist, accelerates
mall intestinal and colonic transit by boosting the peri-
taltic reflex and by decreasing visceral sensitivity in the
pper and lower gastrointestinal tract. It has been shown
o improve symptoms of abdominal pain, bloating, and
onstipation for persons with constipation-predominant
BS. A large placebo-controlled trial38 (n  1519) of
omen with constipation-predominant IBS concluded
hat 12 mg/day of tegaserod significantly improved con-
tipation and abdominal pain and bloating. Another
arge, long-term trial39 involving 579 patients with IBS
ith constipation confirmed this finding. Despite its
otential for treating incontinence associated with con-
tipation, there are no reported data on the effects of
egaserod on incontinence.
Cisapride, a mixed 5-HT3 antagonist/5-HT4 agonist,
timulates motor activity throughout the gastrointestinal
ract by enhancing the release of acetylcholine from the
nteric nervous system. However, it was not found to be
ffective for treating constipation.40,41 Moreover, safety
oncerns42 have resulted in severe restrictions being
laced on prescribing cisapride, so the drug has no role in
he clinical management of constipation. Erythromycin
s often used to stimulate gastrointestinal motility, al-
hough this is an off-label use of the drug. There is no




Impaction usually occurs in the distal colon and
roduces lower abdominal pain and a distended and
ighly compliant rectum; it sometimes results in incon-
inence as the internal anal sphincter relaxes in response
o pressure from the fecal bolus. Impaired anorectal
ensation, lower anal squeeze pressures, reduced integrity
f sphincter and/or pelvic floor muscles, and neurogenic
bnormalities are factors that may promote incontinence
n the presence of fecal impaction.43
Fecal impaction may require manual removal of stool
rom the rectum as a first step in treatment. Further
anagement may include taking steps to treat constipa-
ion such as increasing fiber intake, fluid intake, and
hysical activity. Constipation that does not respond tohese measures may require the judicious use of stool
ofteners, laxatives, tap-water enemas, and possibly the
se of rectal suppositories. Enema and suppository use
hould be limited to 2–3 times weekly. Anticholinergic
nd other medications that lead to constipation and
mpaction should be reduced in dosage or, if possible,
liminated.
A study by Chassagne et al. suggests that elimination
f fecal impaction is critical to improving continence in
ncontinent nursing home residents with constipation.36
hey studied 206 patients with daily fecal incontinence
ssociated with fecal impaction and compared a single
smotic laxative with osmotic laxatives plus weekly en-
mas. Although the enemas did not significantly im-
rove outcomes overall, periodic digital examination
howed that the patients who achieved complete rectal
mptying had 35% fewer episodes of fecal incontinence
han the subjects who continued to experience fecal
mpaction.
Prolapsing Hemorrhoids
Hemorrhoids are blood vessels in the anal canal
hat arise from the hemorrhoidal cushion or plexus orig-
nating from the superior and inferior hemorrhoidal
eins. Hemorrhoids may be internal or external. Internal
emorrhoids may prolapse from the anal canal due to the
ressure of straining during bowel movements, diarrhea,
itting for extended periods, pregnancy, and childbirth.
rolapsing hemorrhoids may partially obstruct defeca-
ion and can cause soilage from the passage of fecal
aterial, mucus, or blood.44 It is estimated that half of
he patients with prolapsing (grades III and IV) hemor-
hoids experience staining of undergarments with fecal
aterial.
Mild cases of hemorrhoids can be relieved by increas-
ng dietary fiber and fluid intake, bathing the anus, or
pplying soothing creams or ointments. Hemorrhoidec-
omy is an effective method for treating more severe
ases. Recent advances in endoscopic evaluation and
reatment have made it possible to obliterate hemor-
hoids through banding ligation. In this procedure, the
linician, using a ligator attached to an endoscope or
nserted through an anoscope, places a tight band around
he enlarged vein, causing the hemorrhoid to throm-
ose.45 In addition to allowing the hemorrhoid to throm-
ose, ligation banding eliminates redundant mucosal
issue and produces submucosal scarring, which decreases
he risk of fecal incontinence secondary to prolapsing
issue.
Preliminary trial results with this type of procedure
















































S62 YOLANDA SCARLETT GASTROENTEROLOGY Vol. 126, No. 187%) with either stage II or stage III hemorrhoids had
o further bleeding complications after a single banding
ession.46 Other investigators found that patients with
tage II hemorrhoids were more likely than patients with
tage III hemorrhoids to achieve excellent results (80%
s. 54%) through endoscopic banding.47 Effects on fecal
ncontinence were not reported.
Conclusion
Treatment of fecal incontinence should focus on
valuating the patient, determining the underlying pa-
hology, and choosing an appropriate medical therapy to
rovide symptomatic relief. For patients with diarrhea,
ngestion of fiber and stool-bulking supplements can
elp form firmer stools. Medications such as loperamide
nd diphenoxylate that slow gastrointestinal transit
ime, reduce stool frequency, inhibit peristalsis, and in-
rease sphincter tone and resting pressure are beneficial
or managing diarrhea. For patients with constipation
nd overflow incontinence, judicious use of stool soften-
rs, bulking agents, stimulant laxatives, and saline lax-
tives can help soften stool consistency, increase stool
ulk, and decrease colonic transit time, thereby decreas-
ng the risk of fecal impaction.
Recent advances in endoscopic hemorrhoidal banding
ave made it possible to more effectively remove pro-
apsing hemorrhoids to eliminate obstruction to defeca-
ion and reduce fecal soilage. Further studies are needed
o specifically assess the effects of endoscopic banding on
ecal incontinence.
Because the pathophysiology of fecal incontinence is
ften complex, future trials should assess the viability of
sing multiple pharmacologic interventions simulta-
eously. Multidisciplinary trials comparing combina-
ions of surgical, medical, and behavioral interventions
re also needed.
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